SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis

Related Experiment Video

Updated: Oct 14, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.1K

Satoru Yokoyama1, Atsushi Takahashi2, Ryota Kikuchi2

  • 1Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan. yokoyama@pha.u-toyama.ac.jp.

Cancer Research
|November 3, 2021
PubMed

Insights

SOX10 hinders melanoma immunogenicity by repressing IRF1 via IRF4. Targeting this SOX10-IRF4-IRF1 axis can improve immunotherapy efficacy, even when JAK-STAT signaling is impaired.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Oncology

Background:

  • Loss-of-function mutations in JAK1/2 reduce cancer cell response to Interferon-gamma (IFNγ) and impair immunogenicity.
  • Understanding compensatory pathways for IFNγ signaling is crucial for effective cancer immunotherapy.

Purpose of the Study:

  • To investigate the role of transcription factor SOX10 in regulating melanoma cell immunogenicity.
  • To identify novel pathways that can overcome JAK-STAT pathway defects in melanoma immunotherapy.

Main Methods:

  • Genetic and pharmacologic approaches were used to study the SOX10-IRF4-IRF1 axis.
  • Investigated the regulation of IRF1 transcription by SOX10 and IRF4.
  • Assessed the impact of SOX10 suppression on combination therapy efficacy in a melanoma model.

Main Results:

  • SOX10 was found to hinder melanoma immunogenicity by repressing IRF1 transcription through the induction of IRF4.
  • The SOX10-IRF4-IRF1 axis regulates PD-L1 expression independently of JAK-STAT pathway activity.
  • Suppression of SOX10 enhanced the efficacy of combined anti-PD-1 antibody and histone deacetylase inhibitor therapy.

Conclusions:

  • A novel SOX10/IRF4 pathway regulates IRF1 induction independently of JAK-STAT signaling.
  • This pathway offers a potential therapeutic target to enhance anti-PD-1 therapy in melanoma.
  • Targeting the SOX10-IRF4-IRF1 axis can 'warm up' the tumor microenvironment in cold melanomas.

More Related Videos

Direct Reprogramming of Mouse Fibroblasts into Melanocytes09:38

Direct Reprogramming of Mouse Fibroblasts into Melanocytes

Published on: August 27, 2021

2.2K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.0K

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
41.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.5K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K